SRRK (Scholar Rock Holding) Quality Rank

View and export this data going back to 2018. Start your Free Trial

What is Scholar Rock Holding Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:

Interest coverage
Zscore
Debt to revenue
Equity to asset
Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:

Operating margin mean rank (10-year mean average profit margine)
Operating margin growth rank
Fscore
Predictability rank
Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
Num of year profit (number of years that is profitable within the last 10 years)
ROIC median (10-year median of ROIC)

Scholar Rock Holding Quality Rank Related Terms

Thank you for viewing the detailed overview of Scholar Rock Holding's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Scholar Rock Holding Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scholar Rock Holding Corp (NAS:SRRK) » Definitions » Quality Rank

Comparable Companies

Traded in Other Exchanges

2QK:Germany

Address

301 Binney Street, 3rd Floor, Cambridge, MA, USA, 02142

Website

https://www.scholarrock.com

Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.

Executives

Edward H Myles	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Mo Qatanani	officer: SVP and Head of Research	301 BINNEY STREET, 3RD FLOOR, C/O SCHOLAR ROCK HOLDING CORP, CAMBRIDGE MA 02142
Caryn Parlavecchio	officer: CHRO	SCHOLAR ROCK HOLDING CORPORATION, 301 BINNEY STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Junlin Ho	officer: General Counsel	301 BINNEY STREET, CAMBRIDGE MA 02142
Jay T. Backstrom	officer: CEO-Elect	SCHOLAR ROCK HOLDING CORPORATION, 301 BINNEY STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Tracey Sacco	officer: Chief Commercial Officer	301 BINNEY STREET, 3RD FLOOR, C/O SCHOLAR ROCK HOLDING CORP, CAMBRIDGE MA 02142
Jing L. Marantz	officer: Chief Medical Officer	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Invus Public Equities, L.p.	10 percent owner	C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
Srinivas Akkaraju	director	565 EVERETT AVENUE, PALO ALTO CA 94301
Samsara Biocapital Gp, Llc	10 percent owner	251 CHURCHILL AVENUE, PALO ALTO CA 94301
Richard Brudnick	director	BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Amir Nashat	director	10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Samsara Biocapital, L.p.	10 percent owner	628 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Amaury Wittouck	10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L2661
Artal Group S.a.	10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661